News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
709,108 Results
Type
Article (42032)
Company Profile (436)
Press Release (666640)
Section
Business (208613)
Career Advice (2020)
Deals (35995)
Drug Delivery (102)
Drug Development (83486)
Employer Resources (170)
FDA (16387)
Job Trends (15072)
News (352519)
Policy (33028)
Tag
Academia (2625)
Alliances (50853)
Alzheimer's disease (1364)
Approvals (16361)
Artificial intelligence (224)
Bankruptcy (367)
Best Places to Work (11841)
Biotechnology (330)
Breast cancer (236)
Cancer (1810)
Cardiovascular disease (143)
Career advice (1683)
CAR-T (133)
Cell therapy (388)
Clinical research (67112)
Collaboration (724)
Compensation (381)
COVID-19 (2628)
C-suite (178)
Data (1702)
Diabetes (223)
Diagnostics (6357)
Earnings (86867)
Employer resources (146)
Events (114608)
Executive appointments (597)
FDA (17342)
Funding (646)
Gene therapy (274)
GLP-1 (694)
Government (4450)
Healthcare (19114)
Infectious disease (2746)
Inflammatory bowel disease (131)
Interviews (311)
IPO (16746)
Job creations (3698)
Job search strategy (1433)
Layoffs (469)
Legal (7968)
Lung cancer (263)
Manufacturing (250)
Medical device (13422)
Medtech (13427)
Mergers & acquisitions (19628)
Metabolic disorders (597)
Neuroscience (1811)
NextGen: Class of 2025 (6750)
Non-profit (4546)
Northern California (2190)
Obesity (330)
Opinion (215)
Patents (175)
People (58263)
Phase I (21081)
Phase II (29625)
Phase III (21886)
Pipeline (788)
Postmarket research (2600)
Preclinical (8978)
Radiopharmaceuticals (258)
Rare diseases (350)
Real estate (6005)
Regulatory (22420)
Research institute (2410)
Resumes & cover letters (351)
Southern California (1894)
Startups (3755)
United States (19587)
Vaccines (636)
Weight loss (231)
Date
Last 7 days (826)
Last 30 days (2652)
Last 365 days (35283)
2025 (5385)
2024 (36302)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33025)
2016 (32348)
2015 (38397)
2014 (32185)
2013 (27110)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (735)
Arizona (219)
Asia (38952)
Australia (6482)
California (5058)
Canada (1755)
China (418)
Colorado (230)
Connecticut (246)
Europe (85022)
Florida (731)
Georgia (171)
Illinois (478)
Indiana (271)
Maryland (776)
Massachusetts (3913)
Michigan (202)
Minnesota (347)
New Jersey (1425)
New York (1436)
North Carolina (915)
Northern California (2190)
Ohio (176)
Pennsylvania (1141)
South America (1107)
Southern California (1894)
Texas (739)
Utah (154)
Washington State (493)
709,108 Results for "sarepta therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Accelerated approval
Inspector General Questions FDA’s Accelerated Approval for Biogen, Sarepta Drugs
An OIG report zeroed in on what it said were three particularly problematic accelerated approvals: Biogen’s Aduhelm, Sarepta’s Exondys and Covis’ Makena.
January 15, 2025
·
2 min read
·
Tristan Manalac
Earnings
Sarepta Previews Q4 Findings, Touts Elevidys Earnings Beat
Sarepta Therapeutics’ Duchenne muscular dystrophy therapy Elevidys handily beat analysts’ expectations in the fourth quarter of 2024, reflecting the biotech’s “world-class” execution, according to BMO Capital Markets analysts.
January 14, 2025
·
2 min read
·
Tristan Manalac
Duchenne muscular dystrophy
Sarepta’s Recent Elevidys Presentations Leave Duchenne Community Wanting
With Sarepta’s gene therapy Elevidys now available to a majority of Duchenne muscular dystrophy patients, experts express cautious optimism while emphasizing the need for further data.
October 28, 2024
·
6 min read
·
Heather McKenzie
Editorial
Sarepta, Biotech’s Regulatory Go-Getter, Signs Standout Rare Disease Deal
Not exactly known for its dealmaking, Sarepta Therapeutics has thrown down a massive wad of cash to work with Arrowhead Pharmaceuticals on RNAi-based medicines.
December 4, 2024
·
3 min read
·
Annalee Armstrong
Duchenne muscular dystrophy
Regenxbio Gears Up to Challenge Sarepta in DMD as Gene Therapy Advances to Pivotal Studies
Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for 2026—potentially posing a threat to Sarepta’s Elevidys.
November 19, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results
February 13, 2025
·
1 min read
Press Releases
Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility
February 17, 2025
·
4 min read
Press Releases
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics
February 10, 2025
·
6 min read
Earnings
Sarepta Halts Development of Next-Gen DMD Drug, Reports Robust Elevidys Sales
The investigational therapy, vesleteplirsen, had been positioned as an updated version of Sarepta’s original exon 51-skipping Duchenne muscular dystrophy drug Exondys 51.
November 7, 2024
·
2 min read
·
Heather McKenzie
Deals
Sarepta Aims Up to $10B at Arrowhead to Diversify Pipeline With RNA Drugs
With Elevidys expansion in hand, Sarepta commits up to $10 billion to develop short interfering RNA–based drugs to build out its pipeline.
November 26, 2024
·
2 min read
·
Kate Goodwin
1 of 70,911
Next
